Brief: Gen Ilac Ve Saglik Urunleri Says Wins Permit For Drug For Treatment of SMA disease From Turkey's SGK
Nov 30 (Reuters) - GEN ILAC VE SAGLIK URUNLERI SANAYI VE
TICARET GENIL.IS :
* WINS PERMIT FOR SMA DRUG
* EXPECTS 1.10-1.25 BILLION LIRA WORTH SALES IN 2023
Source text for Eikon: ID:nIKA7qLdFp
Further company coverage: GENIL.IS
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Gen Ilac ve Saglik Urunleri Sanayi Ticaret
See all newsBrief: Gen Ilac Says It Wins Pharmaceutical Tender In Kazakhstan, Expects $1.19 Million Sales Contribution In 2027
Brief: Gen Ilac Says It Participates In Kazakhstan Drug Procurement Tender Via Med Service Plus Authorized By Kazakhstan Representative Office Of Gen Ilac
Brief: Gen Ilac Says It Signs Supply And Distribution Agreement With Incyte On Oct 9
Brief: Gen Ilac Says It Completes Pharmaceutical Manufacturing Plant Investment In Azerbaijan
Brief: Gen Ilac Says It Is To Start Share Buyback Programme For Max 125 Mln Nominal Shares With Allocated Funds Of 1.5 Bln Lira